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ABSTRACT Xeroderma pigmentosum (XP) patients fail
to remove pyrimidine dimers caused by sunlight and, as a
consequence, develop multiple cancers in areas exposed to
light. The second most common sign, present in 20–30% of XP
patients, is a set of neurological abnormalities caused by
neuronal death in the central and peripheral nervous systems.
Neural tissue is shielded from sunlight-induced DNA damage,
so the cause of neurodegeneration in XP patients remains
unexplained. In this study, we show that two major oxidative
DNA lesions, 8-oxoguanine and thymine glycol, are excised
from DNA in vitro by the same enzyme system responsible for
removing pyrimidine dimers and other bulky DNA adducts.
Our results suggest that XP neurological disease may be
caused by defective repair of lesions that are produced in nerve
cells by reactive oxygen species generated as by-products of an
active oxidative metabolism.
Xeroderma pigmentosum (XP) is an hereditary disease char-
acterized clinically by extreme sensitivity to sunlight, a predis-
position to skin cancer and other dermatological changes in
exposed areas, and progressive neurological abnormalities.
The underlying cause of solar sensitivity is an inability to repair
UV-induced DNA damage (1, 2), and some investigators have
suggested that XP neurological disease, which is particularly
prevalent in groups A and D, is caused by DNA damage in
nerve cells (3, 4). XP can be caused by mutations in any one
of seven genes, XPA through XPG (1). With the exception of
XPE, whose gene product has not been unambiguously iden-
tified, the proteins encoded by each of these genes are essential
for nucleotide excision repair, the primary enzyme system for
removal of bulky DNA lesions (2, 5, 6). Recent studies have
revealed that some of these genes, in addition to DNA repair,
play a role in transcription, thus raising the possibility that XP
neurological abnormalities are caused by defects in transcrip-
tion (7–9). The XPB and XPD gene products are subunits of the
general transcription factor TFIIH (10, 11), so it is conceivable
that the neurological disease in complementation groups (CG)
B and D is caused by defective transcription. Similarly, the
XPG protein binds tightly to TFIIH (12–14) and has been
found in some RNA polymerase II holoenzyme preparations
(15); hence, the neurological disease in the XPG CG may also
be ascribed to a transcription defect. However, neurological
abnormalities also are observed in CG A, but there is no
evidence that the XPA protein has any function other than
DNA repair.
Neurons consume great amounts of molecular oxygen, and
the reactive oxygen species that are by-products of cellular
respiration can cause considerable damage to DNA; if not
repaired, such damage may be the cause of neurodegeneration
in XP patients (3, 4). The major DNA lesions produced by
oxidative damage, 8-oxoguanine (8-OxoG), thymine glycol
(Tg), pyrimidine hydrates, and urea, are nonbulky lesions
thought to be repaired mostly, if not exclusively, by the base
excision pathway that does not depend on XP proteins (16).
There is no evidence that nucleotide excision repair, the repair
system for bulky adducts, contributes substantially to the repair
of these nonbulky lesions. Therefore, it has been proposed (17)
that neuronal death in XP patients is caused by rare bulky
lesions known to be induced by reactive oxygen species (18).
Considering the rarity of such lesions and knowing that the
functionally homologous Escherichia coli (A)BC excinuclease
system removes Tg lesions (19), we reasoned that the more
common, nonbulky lesions induced by oxidative damage (20)
may be the cause of XP neurological disease if the mammalian
nucleotide excision repair system contributes significantly to
the removal of such damaged bases in unaffected individuals.
Hence, we decided to use the XP protein-dependent excision
assay (12, 21, 22) to examine the effect of nucleotide excision
repair on the major DNA lesions caused by oxidative stress
(Fig. 1a).
Tg and 8-OxoG are generated directly by reactions of the
corresponding bases with hydroxyl radicals; urea is a secondary
product generated in substantial quantities by spontaneous
hydrolytic cleavage of Tg. The classical substrate for nucleotide
excision repair, the bulky cis, syn-cyclobutane thymine dimer
(T,.T), was used as a reference lesion. Mammalian nucle-
otide excision repair is initiated by dual incisions, one on each
side of the lesion, resulting in release of oligonucleotides 24-
to 32-nt in length (21). To test for removal of oxidative base
lesions by nucleotide excision, we constructed substrates (Fig.
1b) in which a 139-bp duplex contained the damaged base at
nucleotide 70; for comparison, we used a 140-bp duplex with
T,.T at nucleotides 74–75.
MATERIALS AND METHODS
Cell Lines, Cell-Free Extracts (CFEs), and Purified Repair
Factors. HeLa S3 cells were from the stock of Lineberger
Comprehensive Cancer Center (Chapel Hill, NC). The fol-
lowing Chinese hamster ovary (CHO) cell lines were obtained
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from the American Type Culture Collection Repository
(Rockville, MD): CRL 1859 (AA8, parental cell line), CRL
1862 (UV20, ERCC1), CRL 1865 (UV5, ERCC2, XP-D),
CRL 1866 (UV24, ERCC3, XP-B), CRL 1860 (UV41,
ERCC4, XP-F), and CRL 1867 (UV135, ERCC5, XP-G). The
National Institute of General Medical Sciences Human Mu-
tant Cell Repository (Coriell Institute, Camden, NJ) provided
these human cell lines: XP-A (XP20S, GM02345), XP-B
(XP11BE, GM02252), XP-C (XP1BE, GM02246; XP3BE,
GM02248; XP21RO, GM00709), XP-D (XP17BE, GM02253;
XP7BE, GM02485), XP-F (XP2YO, GM08437), and XP-G
(XP2BI, GM03021). Cells were cultured as described (22), and
CFEs were prepared from cells in exponential growth phase
according to well established methods (23) and stored at
280°C as described (24). The six factors that reconstitute
human excision nuclease were purified from HeLa cells (RPA,
TFIIH) or as recombinant proteins (XPA, XPC●HHR23B,
XPF●ERCC1, XPG) as described (12, 25–28).
Preparation of Substrates. Double-stranded DNA mole-
cules were prepared by phosphorylation, annealing, and liga-
tion of six partially overlapping oligonucleotides as described
(29), using T4 DNA polynucleotide kinase and T4 DNA ligase
(New England BioLabs) to generate duplexes with 1-nt over-
hangs at the 59 ends. The oligomers containing centrally
located Tg, urea, and T,.T lesions were prepared as de-
scribed (30, 31), and the oligomer containing 8-OxoG was
obtained from the Midland Certified Reagent Company (Mid-
land, TX). All oligomers used for substrates were purified by
HPLC; NMR was used to characterize the oligomer containing
Tg (30), and the composition of the 8-OxoG oligomer was
verified by mass spectral analysis (Midland Certified Reagent
Company). The damaged oligomers were phosphorylated with
[g-32P]ATP (7000 Ciymmol; 1Ci 5 37 GBq) and used for
substrate preparation. For DNA containing oxidative base
lesions, the substrate was a 139-bp duplex with the adduct at
nucleotide 70 of one strand and 32P label at the 6th phos-
phodiester bond 59 to the lesion. For comparison, we used a
140-bp duplex with T,.T at nucleotides 74–75 and 32P label
at the 13th bond 59 to the photoproduct. Because the manip-
ulations used for substrate purification may induce abasic (AP)
sites in the DNA, we tested the integrity of the Tg and 8-OxoG
substrates by incubating the DNA with human AP endonu-
clease as described (32). We found that '1% of the 8-OxoG
and 8% of the Tg substrate molecules were incised under
conditions in which a bona fide AP site was digested to
completion.
Excision Assays. The excision reactions with either CFE or
purified repair factors were conducted under substrate-
limiting conditions (data not shown). For assays with extracts
based on a single time point, 50 mg of CFE (25 mg each for
complementation assays) and 12.6 fmol of pBR322 were mixed
in 25 ml of reaction buffer as described (24). The repair
reaction was at 30°C for 60 min and was initiated by addition
of substrate DNA (40 fmol of 8-OxoG or 15 fmol of Tg). For
the time course with HeLa CFE, 150 mg of extract and 60 fmol
of pBR322 were mixed with substrate DNA (90 fmol of
8-OxoG or 120 fmol of Tg) in 75 ml of reaction buffer, and
18-ml aliquots were removed at the indicated time points. For
the kinetic experiments with CHO AA8 extract, substrate
DNA (100 fmol) was incubated at 30°C with 330 mg of CFE and
60 fmol of pBR322 in 125 ml of reaction buffer, and 18-ml
aliquots were removed at the indicated time points. For the
excision reactions with purified repair factors, substrate DNA
(30 fmol) was incubated at 30°C for 2.5 h with the indicated
repair factors in 25 ml of reaction buffer similar to that
described (25). Processing of DNA, PAGE, autoradiography,
and quantitation of repair with an AMBIS Systems Scanner
have been described (24). The level of repair for each reaction
was determined from the radioactivity migrating as 20–30
mers as a percentage of the total radioactivity in the lane. We
have shown previously that, after incubation with CFE and
resolution by gel electrophoresis, fragments in this size range
contain the excised thymine dimer (33), psoralen monoadduct
(T.B., D. Mu, and A.S., unpublished work), ABPD (2-
aminobutyl-1, 3-propanediol) synthetic analog of an AP site
(J.T.R. and A.S., unpublished work), ABPD site with a cho-
lesterol side chain (29), and cisplatin GG diadduct (J. C. Huang
and A.S., unpublished work).
RESULTS
Removal of Oxidative DNA Damage by Extracts. The 8-
OxoG- and Tg-containing DNAs were tested for removal by
nucleotide excision repair using HeLa CFE known to be
capable of excising thymine dimers (21). Fig. 2a shows that, at
early time points, both lesions were excised by HeLa CFE
primarily as 26-nt long oligomers; at later time points, smaller
species appeared, in part because of exonucleolytic digestion of
excised fragments (35). CFE prepared from human XP cell
lines (XP-A, XP-B, XP-C, XP-D, XP-F, and XP-G) failed to
excise these lesions in oligonucleotides (data not shown),
consistent with the requirement of all XP proteins for nucle-
otide excision repair. However, some of the CFE from XP
lymphoblastoid and fibroblast cell lines gave high background
caused by degradation of the DNA by nonspecific endonucle-
ases. Hence, we decided to investigate the requirement for XP
proteins and to characterize the excision reaction further by
using either CFE from CHO cell lines mutated in XP genes or
FIG. 1. Substrates used in this study. (a) Structures of the base
lesions; dR, deoxyribose. (b) Schematic of duplexes used in the
excision assay. Linear duplex molecules, 139 or 140 bp in length, were
prepared by phosphorylation, annealing, and ligation of six overlap-
ping oligonucleotides; p, position of the radiolabel. (Upper) X denotes
8-OxoG, Tg, or urea.
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the reconstituted human excision nuclease system, the dual
incision activity that requires all XP proteins. We used the
CHO AA8 cell line and its mutant derivatives for experiments
with CFE because of the ease of growing these cells and
obtaining high quality extracts. Furthermore, both genetic (36)
and biochemical (22) data show that the human and hamster
nucleotide excision repair proteins are interchangeable and,
hence, any result obtained with CFE from these cell lines
should be applicable to human excision repair.
Results presented in Fig. 2 b and c demonstrate that the
CHO AA8 CFE excised both lesions and that CFEs from cell
lines (CGs) with mutations in ERCC1 (CG1), XPD (CG2),
XPB (CG3), XPF (CG4), and XPG (CG5) genes were as
defective in removing 8-OxoG and Tg as they are in removing
T,.T (22). Because one of the hallmarks of nucleotide
excision repair is an essentially infinite substrate range (5, 35),
it was not surprising to find that nucleotide excision repair
removes nonbulky lesions caused by oxidative damage. The
important question is whether these nonbulky lesions are
removed at a physiologically relevant rate. To assess the
potential significance of excision of oxidative lesions by nu-
cleotide excision repair, we compared the rates of removal of
these lesions to that of T,.T, the classical substrate for
nucleotide excision repair used in the vast majority of in vivo
assays that measure nucleotide excision repair on the basis of
the disappearance of pyrimidine dimers from cellular DNA (2,
36).
Fig. 3 shows the results of kinetic assays conducted with
CHO AA8 CFE and the four substrates illustrated in Fig. 1. All
four lesions were released primarily as oligonucleotides 20–30
nt in length, with the shorter species being more abundant with
the oxidative damage substrates. At later time points, the
smaller species predominated with all four substrates, similar
to the results obtained with HeLa CFE. A quantitative analysis
of the results shown in Fig. 3 a–d, combined with data from
other experiments performed under identical conditions, is
presented in Fig. 3e. As is apparent, 8-OxoG was excised at a
1.5-fold faster rate than T,.T, which was excised at about a
3-fold faster rate than Tg or urea. With either the Tg or urea
substrates, the excision reaction was essentially complete at 20
min, and excision of 8-OxoG and T,.T continued to increase
during the first 60 min of incubation. Although we have no
explanation for these different kinetics, these results clearly
show that oxidative DNA lesions are repaired in vitro at rates
comparable to that of T,.T, the reference bulky lesion.
Therefore, we consider the removal of 8-OxoG, Tg, and urea
by the nucleotide excision repair system to be physiologically
relevant.
The results shown in Figs. 2 and 3 suggest that the nucleotide
excision system, as defined by the requirement for all proteins
encoded by the XP genes and the dual incision mode, removes
the major oxidative base lesions. However, data obtained with
CFE have certain limitations. For instance, these extracts
contain proteins that specifically bind to oxidative base lesions
(37–41), and recognition by such proteins could be necessary
for the subsequent action of the mammalian excision nuclease.
It is also possible that nucleotide excision repair enzymes act
on a secondary lesion, a glycosylase-generated AP site, known
to be a weak substrate for HeLa CFE in our in vitro system (5,
35). However, the possibility that the repair signal was gener-
ated by an AP site was eliminated by the following observa-
tions. The 8-OxoG substrate contains at most 1% AP site, and
we have reported that, under optimal conditions, only 4% of
AP substrate can be excised in our system (35). Hence, the
maximum excision that may arise from an AP contaminant
would be 0.04% of the substrate. In fact, we obtain '2%
excision with the 8-OxoG substrate, indicating that the excised
lesion is 8-OxoG itself and not an AP site. This is further
supported by the finding that the Tg substrate, which contains
more AP sites than the 8-OxoG substrate, is in fact a weaker
substrate in vitro for the excision nuclease. Alternatively, it can
be argued that cleavage by glycosylaseyAP endonuclease is a
prerequisite for excision nuclease activity. Cleavage of these
substrates by the joint actions of glycosylase and AP endonu-
clease is expected to give rise to a 69-nt fragment, and such a
band is seen in our assays (Figs. 2a and 3a). However, even
incubation of 8-OxoG, Tg, and urea substrates in reaction
buffer without CFE generated this fragment; upon incubation
with CFE, there was no or only a modest increase in the level
of this cleavage product, which varied from 1 to 5% of input
substrate in different preparations (data not shown). Hence,
we conclude that only a minor fraction of the 69 mer seen in
our excision experiments is produced by glycosylaseyAP en-
donuclease action. To ascertain that the excision of oxidative
base damage that we detect in CFE is bona fide nucleotide
excision repair, which requires all excision repair factors, we
conducted experiments with purified repair proteins.
Excision of Oxidative Damage by Purified Repair Factors.
Six repair factors consisting of XPA, RPA, TFIIH (XPB and
XPD plus other polypeptides), XPC●HHR23B, XPG, and
XPF●ERCC1 are necessary and sufficient to reconstitute the
human excision nuclease (12, 25). Hence, the four substrates
that were used with CFE also were tested with the reconsti-
tuted system. All four lesions were excised by the reconstituted
system (Fig. 4a), and omission of individual repair factors
abolished excision of 8-OxoG (Fig. 4b) as well as T,.T (25),
Tg, and urea (data not shown). Quantitative analysis of the
data with the reconstituted system revealed that levels of
excision for all four lesions were within a factor of 2 of one
another (Fig. 4c). These results demonstrate that 8-OxoG, Tg,
and urea can be excised in vitro by the human excision nuclease.
FIG. 2. Excision of oxidative DNA lesions by human and rodent
CFEs. (a) Autoradiograph of sequencing gel showing time course of
excision by HeLa CFE. In lanes 1 and 4, substrate DNA was resolved
without incubation in reaction buffer. (b) Excision of 8-OxoG by CFE
from CHO AA8 and its excision repair mutant derivatives. The mutant
cell lines used were UV20, UV5, UV24, UV41, and UV135 repre-
sentative of CG 1–5, respectively. (c) Excision of Tg by CHO AA8 CFE
and the same set of mutant cell lines. In a, the entire gel is shown; in
b and c, only the region encompassing the excision products is shown.
For the 60-min time points with HeLa CFE, the excision products were
0.1% of input DNA (a, lanes 3 and 6) whereas the level of excision with
AA8 CFE was '2% for 8-OxoG (b, lane 1) and 0.7% for Tg (panel
c, lane 1). As with the T,.T substrate (22), the mixture of two mutant
CFEs typically gave '50% of the wild-type signal. The faint bands
visible in lane 6 (c) are due to degradation of the substrate by nucleases
in the UV135 CFE.
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We believe that these findings are relevant to the progression
of neurological disease in XP patients.
DISCUSSION
Two hereditary diseases in which patients present signs of
neurological abnormalities are known to be caused by muta-
tions in genes that affect DNA repair: XP and Cockayne’s
syndrome (CS) (1, 2, 7, 8). In light of our results and of recent
reports on the possible cause of neurological disease in these
patients (7, 42, 43), we wish to reconsider the models proposed
for the neurodegeneration associated with CS and XP. CS
patients suffer acute sun sensitivity, severe cachetic dwarfism,
and developmental neurological abnormalities caused primar-
ily by demyelination. Cultured CS cells are defective in tran-
scription-coupled repair (TCR) of pyrimidine dimers (44) and
Tgs (43). Mutations in two genes exclusively associated with
CS, CSA and CSB, and in three genes essential for excision
repair, XPB, XPD, and XPG, can cause CS. Of interest,
although CSA and CSB mutations affect only TCR of pyrim-
idine dimers and other bulky adducts, mutations in XPB, XPD,
and XPG greatly reduce or abolish overall repair as well (1, 2).
A finding with potential implications for the pathogenesis of
CS is that not only nucleotide excision repair of T,.T, but
also base excision repair of Tg, is coupled to transcription (43).
However, in contrast to TCR of T,.T, which requires all six
excision repair factors, TCR of Tg depends on the XPG
polypeptide but not on XPA or XPF and does not require the
39 nuclease function of XPG (43). Thus, certain XPG muta-
tions that completely abolished excision repair of T,.T did
not affect the rate of either overall or TCR of Tg (43). In
contrast, XPG null mutations completely eliminated TCR of
both T,.T and Tg, totally abolished excision of T,.T, and
moderately reduced the rate of transcription-independent
repair of the Tg lesion (43).
Based on these data, it was proposed that Tg is removed
from human chromosomes by two pathways (43). The first
pathway (fast rate) requires the physical presence of XPG (but
not its nuclease activity) 1 CSB protein 1 (glycosylaseyAP
endonuclease) but not the XPA or XPF proteins; this is TCR
of Tgs. The second pathway (intermediate rate) requires XPG
(but not its nuclease activity) 1 (glycosylaseyAP endonucle-
ase) but not the XPA, XPF, or CSB proteins; this is XPG-
dependent genome overall repair of Tg lesions. The require-
ment for glycosylaseyAP endonuclease activity in these two
pathways is quite likely but has not been experimentally
demonstrated. Similarly, it has not been shown whether these
two pathways remove oxidative damage other than Tg. The
third pathway (slow rate) that we describe in this study is
nucleotide excision repair, which requires the entire set of
excision repair proteins including XPA, XPB, XPC, XPD,
XPF, and XPG as well as the other polypeptides necessary for
excision of T,.T (12, 25). The properties of the three
pathways may help explain the different neuropathologies in
the two diseases. Although there is no absolute demarcation
between the neuropathology of XP and CS, degenerative
changes predominate in XP and developmental abnormalities
predominate in CS (45, 46). It is conceivable that the two fast
pathways, which are dependent on XPG but independent of
XPA and XPF, play an important role in maintaining genomic
integrity during neuroskeletal development. The recent find-
ings that null mutations of genes essential for base excision, AP
FIG. 3. Time course of excision of oxidative base damage by mammalian excision nuclease using CHO CFEs. Sequencing gels show the results
of kinetic experiments conducted as described in the text. (a) The entire gel is shown; (b–d) only the region encompassing the excision products
is shown. In the time 0 lanes, substrate DNA was resolved without incubation in reaction buffer. (e) Quantitative analyses of the data shown in
a–d and of additional experiments conducted under identical conditions; n 5 2–5 experiments except the 90- and 120-min time points with the urea
substrate. The bars indicate SEs; in these experiments, 200 amol of excision products represents '1.4% excision of input DNA.
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endonuclease and DNA polymerase b, cause embryonic le-
thality (47, 48) underscore the importance of base excision
repair during development.
In contrast, the comparatively slower nucleotide excision
repair pathway for the removal of the most common oxidative
lesions, such as 8-OxoG and Tg, may play a more significant
role in helping to maintain the long term genetic integrity of
fully differentiated neurons, and defects in this pathway may
lead to XP neurological disease. There are three caveats to this
model for neurodegeneration in XP: (i) Our data simply show
that the human nucleotide excision repair system can remove
8-OxoG and Tg in vitro; the rate may be too slow to be of
relevance in vivo. However, the fact that the classical T,.T
substrate for excision repair is removed at an intermediate rate
compared with 8-OxoG and Tg suggests that the removal of
oxidative base damage by nucleotide excision repair is fast
enough to be physiologically significant. (ii) If nucleotide
excision repair is essential to prevent neurodegeneration, one
would expect all XP patients to exhibit neurological disease;
yet it is reported that only 20–30% of patients exhibit neuro-
logical signs and some CGs such as XP-C are, as a rule, free
of neurological disease (1, 49). However, a careful analysis of
available case histories of XP patients and, where available, the
nature of the mutation, suggests that, if they do not succumb
to skin cancers, most XP patients will eventually develop
neurological disease. Patients with leaky mutations in any XP
gene tend to develop the disease later in life compared with
patients with null mutations; XP-C individuals carry out
normal TCR (50, 51) and hence develop neurological symp-
toms only at a relatively advanced age compared with other XP
patients (46, 52). (iii) If nucleotide excision repair plays a
significant role in repairing the most abundant lesions of
oxidative DNA damage, cultured XP cells would be expected
to be hypersensitive to ionizing radiation, which causes DNA
damage by generating hydroxyl radicals that produce 8-OxoG
and Tg in DNA. Yet, as a rule, XP cell lines are not hyper-
sensitive to x-ray killing (1). However, killing by x-rays is largely
due to double-strand breaks induced directly as evidenced by
the extreme sensitivity of scid mutants to killing by ionizing
radiation (53).
The experiments reported in this paper were conducted
under substrate limiting conditions and hence the rates contain
both Km and kcat components and may be taken as approximate
values for catalytic efficiency (kcatyKm). Looked at in this light,
clearly, the major lesions of oxidative damage are repaired with
efficiency comparable to that for the major UV photoproduct.
From a cellular perspective, the two types of lesions differ in
that Tg and other oxidative lesions can also be repaired by
glycosylases whereas, in humans, only nucleotide excision
repair can remove pyrimidine dimers, which are the causative
lesions of XP dermatological symptoms. However, it is quite
possible that the level and activities of glycosylases in neurons
are insufficient to deal with the large amount of oxidative
damage generated in these cells and that nucleotide excision
repair plays a major role in defending neural cells against
oxidative damage. Further research on relative activities of
base excision and nucleotide excision repair systems in various
types of cells and tissues are needed to examine this possibility.
In summary, our results suggest that the defective repair of
nonbulky lesions, such as 8-OxoG and Tg, in XP patients may
FIG. 4. Excision of oxidative DNA lesions by reconstituted human excision nuclease. (a) Autoradiograph of sequencing gel showing excision
by the XP-dependent reconstituted system. (b) Repair factor omission experiment (25) with 8-OxoG. For these experiments, substrate DNA was
resolved in the lanes designated ‘‘2 Repair Factors’’ or ‘‘All Proteins Omitted’’ without prior incubation in reaction buffer. (c) For quantitative
analysis of excision of oxidative damage with the reconstituted system, the averages of two experiments are plotted. For these experiments, 60 amol
of excision products corresponds to '0.2% excision of input DNA.
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be the cause of neurodegeneration in XP. Furthermore, these
results lend support to DNA damage models for other neu-
rodegenerative diseases (54). Although such diseases have not
been correlated with overt defects in known DNA repair
pathways, it is possible that, under certain conditions, oxidative
base damage is so extensive that, even in repair proficient
individuals, all three pathways discussed above are saturated
and the remaining lesions cause neuron death. There is
abundant experimental as well as clinical data suggesting that
oxidative DNA damage contributes to tissue damage in stroke,
trauma, and some chronic neurological disorders (34).
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